• -
  • English
  • Japanese
  • Korean
市場調查報告書
商品編碼
1008124

白細胞介素抑制劑的全球市場(2020年∼2026年)

Global Interleukin Inhibitors Market 2020-2026
出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期間(2021-2027年)，全球白細胞介素抑製劑市場預計將以11.2%的適度年複合成長率成長。推動市場成長的主要因素包括關節炎、哮喘、濕疹、炎症性腸病 (IBD)、牛皮癬等各種疾病在全球範圍內的患病率不斷上升。推動市場成長的其他一些因素是全球正在進行的各種臨床試驗。例如，根據國家臨床試驗(NCT)登記處，截至2020年12月，正在進行200多項臨床試驗，涉及針對各種適應症的不同開發階段的美國白細胞介素抑製劑。因此，這也是在預測期內為市場成長創造廣闊空間的主要因素。

本報告提供白細胞介素抑制劑的世界市場調查，市場概要，市場成長要素及阻礙因素分析，市場機會，各產品類型、用途、地區的市場規模的變化與預測，競爭情形，主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 有競爭力的儀表板
  • 重要的策略分析
  • 主要企業分析
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Johnson and Johnson Services Inc.
    • Novartis AG

第4章 市場決策要素

  • 動機
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 各產品類型
    • IL-1抑制劑
    • IL-5抑制劑
    • IL-6抑制劑
    • IL-17抑制劑
    • IL-23抑制劑
  • 各用途
    • 關節炎
    • 氣喘
    • 濕疹
    • 發炎性腸道疾病(IBD)
    • 乾癬
    • 其他(移植排斥反應)

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • AbbVie, Inc.
  • AstraZeneca Plc
  • Bausch Health Co. Inc.
  • Bristol-Myers Squibb Co.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries, Ltd
目錄
Product Code: OMR2023417

Global Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027

The global Interleukin Inhibitors market is projected to grow at a modest CAGR of 11.2% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the rising prevalence of various disorders such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others across the globe. Some other factors that drive the market growth are the various ongoing clinical trials across the globe. For instance, as per the National Clinical Trial (NCT) Registry, more than 200 clinical trials were going on, as of December 2020, regarding the interleukin inhibitors in the US across different phases of development for various indications. Hence, this is also a major factor that creates a wide scope for the growth of the market over the forecast period.

The global Interleukin Inhibitors market is segmented on the basis of product type and applications. Based on the product type, the market is segmented as IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. The IL-17 inhibitors segment is likely to register a significant market value over the forecast period. Based on the applications, the market is segmented as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. The psoriasis segment is likely to register a significant market value over the forecast period.

Further, based on the geography, the global Interleukin Inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is likely to hold a most substantial share in the market attributing to the presence of the key market giants in the region. Among the region, the US is further estimated to register substantial growth over the forecast period.

Furthermore, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. are some of the prominent players functioning in the global Interleukin Inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.

RESEARCH METHODOLOGY

The market study of the global Interleukin Inhibitors market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for Interleukin Inhibitors manufacturers, pharmaceutical companies, and other related companies, along with government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Interleukin Inhibitors Market Research and Analysis by Product Type

2. Global Interleukin Inhibitors Market Research and Analysis by Applications

The Report covers:

  • Comprehensive research methodology of the global Interleukin Inhibitors market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Interleukin Inhibitors market.
  • Insights about market determinants which are stimulating the global Interleukin Inhibitors market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Eli Lilly and Co.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. F. Hoffmann-La Roche Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. GlaxoSmithKline Plc
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Johnson and Johnson Services Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Novartis AG
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Interleukin Inhibitors Market by Product Type
    • 5.1.1. IL-1 Inhibitors
    • 5.1.2. IL-5 Inhibitors
    • 5.1.3. IL-6 Inhibitors
    • 5.1.4. IL-17 Inhibitors
    • 5.1.5. IL-23 Inhibitors
  • 5.2. Global Interleukin Inhibitors Market by Application
    • 5.2.1. Arthritis
    • 5.2.2. Asthma
    • 5.2.3. Eczema
    • 5.2.4. Inflammatory Bowel Disease (IBD)
    • 5.2.5. Psoriasis
    • 5.2.6. Others (Transplant Rejection)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. ASEAN
    • 6.3.5. South Korea
    • 6.3.6. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie, Inc.
  • 7.2. AstraZeneca Plc
  • 7.3. Bausch Health Co. Inc.
  • 7.4. Bristol-Myers Squibb Co.
  • 7.5. Regeneron Pharmaceuticals, Inc.
  • 7.6. Sanofi SA
  • 7.7. Sun Pharmaceutical Industries Ltd.
  • 7.8. Teva Pharmaceuticals Industries, Ltd

LIST OF TABLES

  • 1. GLOBAL INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL IL-1 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL IL-5 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL IL-6 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL IL-17 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL IL-23 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 8. GLOBAL INTERLEUKIN INHIBITORS FOR ARTHRITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL INTERLEUKIN INHIBITORS FOR ASTHMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL INTERLEUKIN INHIBITORS FOR ECZEMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL INTERLEUKIN INHIBITORS FOR INFLAMMATORY BOWEL DISEASE (IBD) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL INTERLEUKIN INHIBITORS FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 16. NORTH AMERICAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 18. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 19. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
  • 20. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 24. REST OF THE WORLD INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL INTERLEUKIN INHIBITORS MARKET SHARE BY PRODUCT TYPE, 2020 VS 2027 (%)
  • 2. GLOBAL INTERLEUKIN INHIBITORS MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
  • 3. GLOBAL INTERLEUKIN INHIBITORS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 4. US INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 5. CANADA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 6. UK INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 7. FRANCE INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 8. GERMANY INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 9. ITALY INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 10. SPAIN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 11. ROE INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 12. INDIA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 13. CHINA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 14. JAPAN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 15. ASEAN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 16. SOUTH KOREA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. REST OF ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
  • 18. REST OF THE WORLD INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)